CARL ALLEN to Xanthogranuloma, Juvenile
This is a "connection" page, showing publications CARL ALLEN has written about Xanthogranuloma, Juvenile.
Connection Strength
2.058
-
Histiocytic Disorders of Childhood. Pediatr Rev. 2022 Oct 01; 43(10):561-571.
Score: 0.853
-
Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders. Hematology Am Soc Hematol Educ Program. 2015; 2015:559-64.
Score: 0.499
-
Neuroimaging in Pediatric Patients with Juvenile Xanthogranuloma of the CNS. AJNR Am J Neuroradiol. 2022 11; 43(11):1667-1673.
Score: 0.214
-
Histiocytic disorders. Nat Rev Dis Primers. 2021 10 07; 7(1):73.
Score: 0.199
-
Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget. 2017 Jul 11; 8(28):46065-46070.
Score: 0.148
-
Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014 Mar; 61(3):479-87.
Score: 0.114
-
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014 Nov 06; 124(19):3007-15.
Score: 0.030